JPWO2022245757A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022245757A5 JPWO2022245757A5 JP2023571272A JP2023571272A JPWO2022245757A5 JP WO2022245757 A5 JPWO2022245757 A5 JP WO2022245757A5 JP 2023571272 A JP2023571272 A JP 2023571272A JP 2023571272 A JP2023571272 A JP 2023571272A JP WO2022245757 A5 JPWO2022245757 A5 JP WO2022245757A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- moiety
- independently
- moi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189503P | 2021-05-17 | 2021-05-17 | |
| US63/189,503 | 2021-05-17 | ||
| PCT/US2022/029533 WO2022245757A1 (en) | 2021-05-17 | 2022-05-17 | Compositions including conjugated therapy enhancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024519031A JP2024519031A (ja) | 2024-05-08 |
| JP2024519031A5 JP2024519031A5 (https=) | 2025-05-23 |
| JPWO2022245757A5 true JPWO2022245757A5 (https=) | 2025-05-23 |
Family
ID=84140038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571272A Pending JP2024519031A (ja) | 2021-05-17 | 2022-05-17 | コンジュゲート療法エンハンサーを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240238436A1 (https=) |
| EP (1) | EP4351658A4 (https=) |
| JP (1) | JP2024519031A (https=) |
| KR (1) | KR20240012376A (https=) |
| CN (1) | CN117295527A (https=) |
| AU (1) | AU2022277840A1 (https=) |
| BR (1) | BR112023023506A2 (https=) |
| CA (1) | CA3219475A1 (https=) |
| IL (1) | IL307746A (https=) |
| MX (1) | MX2023013274A (https=) |
| PH (1) | PH12023553152A1 (https=) |
| WO (1) | WO2022245757A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX421628B (es) * | 2017-07-26 | 2025-03-14 | Kleo Pharmaceuticals Inc | Compuestos abt universales y usos de los mismos |
| US12364766B2 (en) * | 2018-04-09 | 2025-07-22 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| WO2019241609A1 (en) * | 2018-06-15 | 2019-12-19 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
| JP2023501720A (ja) * | 2019-11-18 | 2023-01-18 | クレオ ファーマシューティカルズ， インコーポレイテッド | 指向性コンジュゲーション技術 |
| JP2024509282A (ja) * | 2021-03-10 | 2024-02-29 | バイオヘイブン・セラピューティクス・リミテッド | ガラクトース欠損免疫グロブリンの二官能性分解剤 |
| US20240252674A1 (en) * | 2021-05-17 | 2024-08-01 | Biohaven Therapeutics Ltd. | Agents for directed conjugation techniques and conjugated products |
| CA3219550A1 (en) * | 2021-05-19 | 2022-11-24 | Gene M. Dubowchik | Antibody drug conjugates using mates technology for delivering cytotoxic agents |
| WO2023043861A2 (en) * | 2021-09-16 | 2023-03-23 | Biohaven Therapeutics Ltd. | Conjugated antibodies for treating diseases |
-
2022
- 2022-05-17 CA CA3219475A patent/CA3219475A1/en active Pending
- 2022-05-17 IL IL307746A patent/IL307746A/en unknown
- 2022-05-17 EP EP22805273.4A patent/EP4351658A4/en active Pending
- 2022-05-17 JP JP2023571272A patent/JP2024519031A/ja active Pending
- 2022-05-17 WO PCT/US2022/029533 patent/WO2022245757A1/en not_active Ceased
- 2022-05-17 KR KR1020237039153A patent/KR20240012376A/ko active Pending
- 2022-05-17 CN CN202280034211.XA patent/CN117295527A/zh active Pending
- 2022-05-17 PH PH1/2023/553152A patent/PH12023553152A1/en unknown
- 2022-05-17 BR BR112023023506A patent/BR112023023506A2/pt unknown
- 2022-05-17 MX MX2023013274A patent/MX2023013274A/es unknown
- 2022-05-17 US US18/555,855 patent/US20240238436A1/en active Pending
- 2022-05-17 AU AU2022277840A patent/AU2022277840A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7073266B2 (ja) | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス | |
| CN101541347B (zh) | 药物载体、其合成及其使用方法 | |
| ES2618832T3 (es) | Composición TNFR-FC estabilizada que comprende arginina | |
| JP6426107B2 (ja) | Ａｐｊ受容体アゴニストおよびその使用 | |
| Danial et al. | Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation | |
| SE462261B (sv) | Farmaceutisk komposition och konjugat av melfalan och normalt humanimmunoglobulin med antitumoerverkan samt foerfarande foer dess framstaellning | |
| RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
| EA200001217A1 (ru) | Лекарственный комплекс | |
| KR19990022573A (ko) | 방사성 의약품을 제조하기 위한 안정한 시약 | |
| JP2008525491A5 (https=) | ||
| JP2014062128A (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| IL266202B2 (en) | Antibody-conjugated cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide γ receptors | |
| PL186949B1 (pl) | Fizjologicznie czynny koniugat PEG-IFN-alfa, sposób jego wytwarzania oraz zawierające go kompozycjefarmaceutyczne | |
| CA3063871A1 (en) | Cyclodextrin protein drug conjugates | |
| CN102333788A (zh) | 因子viii的修饰 | |
| RO118568B1 (ro) | Preparate lichide, stabile, de imunoglobuline, si procedeu de obtinere a acestora | |
| JP2019510735A5 (https=) | ||
| WO2021080008A1 (ja) | １価ｃｃａｐ生成物の製造方法 | |
| KR20050120663A (ko) | 장기간 작용하는 생물학적 활동 컨쥬게이트들 | |
| US6365592B1 (en) | Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP-1B) | |
| ES2564144T3 (es) | Derivados de 6-[2-(fosfonometoxi)alcoxi] pirimidina que tienen actividad antivírica | |
| AU2007345280A1 (en) | Polymer-linked-bisphosphonate inhalant formulations and methods for using the same | |
| JP7733664B2 (ja) | Ｅｐｉ－ｘ４系ペプチドおよびその誘導体 | |
| WO2019034175A1 (zh) | 一种非天然鹅膏毒肽类抗体偶联物 | |
| JPWO2022245757A5 (https=) |